Nefazodone Hydrochloride

HCID 54911CAS 82752-99-6

基本情報

標準SMILES
CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1.Cl
InChIKey
DYCKFEBIOUQECE-UHFFFAOYSA-N
分子式
C25H33Cl2N5O2
平均分子量
506.5 g/mol
単同位体質量
505.20113066

概要

Nefazodone hydrochloride is a hydrochloride. It contains a nefazodone.

名称と識別子

優先名称
Nefazodone Hydrochloride
IUPAC
2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one;hydrochloride

名称と別名

NEFAZODONE HYDROCHLORIDE82752-99-6Nefazodone HclDutoninSerzoneBMY 13754MJ 13,754-1DTXSID8046088MJ-13754-1BMY-1375427X63J94GRNSC-760344
名称をさらに表示
CHEBI:7495DTXCID60260882-(3-(4-(3-chlorophenyl)piperazin-1-yl)propyl)-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one hydrochlorideNefazadone HCl2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-(2-phenoxyethyl)-2,4-dihydro-3H-1,2,4-triazol-3-one hydrochlorideRefChem:57774MenfazonaReseril

データベース識別子

CAS
82752-99-6
PubChem CID
54911
DTXSID
DTXSID8046088
ChEMBL
CHEMBL1200492
ChEBI
CHEBI:7495
UNII
27X63J94GR
EC Number
875-483-1

物性

構造計算による物性

極性表面積
51.6 Ų
水素結合供与体数
1
水素結合受容体数
5
回転可能結合数
10
重原子数
34

実験および物理化学的性質

Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

安全と法規制

GHS分類

GHS Classification · 4 件

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Regulatory InformationNefazodone hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesSkin Irrit. 2 (100%)

毒性情報

Treatment · 1 件

Treatment should consist of those general measures employed in the management of overdosage with any antidepressant. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Due to the wide distribution of nefazodone in body tissues, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for nefazodone are known. (L1712)

Health EffectsSerious side effects include an allergic reaction, fainting, or painful/prolonged erection. [Wikipedia]
Exposure RoutesNefazodone is rapidly and completely absorbed. Its absolute bioavailability is low (about 20%).
Toxicity Summary · 1 件

Within the serotonergic system, nefazodone acts as an antagonist at type 2 serotonin (5-HT<sub>2</sub>) post-synaptic receptors and, like fluoxetine-type antidepressants, inhibits pre-synaptic serotonin (5-HT) reuptake. These mechanisms increase the amount of serotonin available to interact with 5-HT receptors. Within the noradrenergic system, nefazodone inhibits norepinephrine uptake minimally. Nefazodone also antagonizes alpha(1)-adrenergic receptors, producing sedation, muscle relaxation, and a variety of cardiovascular effects. Nefazodone's affinity for benzodiazepine, cholinergic, dopaminergic, histaminic, and beta or alpha(2)-adrenergic receptors is not significant.

Signs and SymptomsCases of life-threatening hepatic failure have been reported in patients treated with nefazodone.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

Hepatic. Route of Elimination: Nefazodone is extensively metabolized after oral administration by n-dealkylation and aliphatic and aromatic hydroxylation, and less than 1% of administered nefazodone is excreted unchanged in urine. Half Life: 2-4 hours

FDA Pharmacological Classification · 2 件

NEFAZODONE HYDROCHLORIDE

Serotonin Reuptake Inhibitor [EPC]

MeSH Pharmacological Classification · 3 件

Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS.

A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.

Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.

用途と製造

UsesNefazodone (sold as Serzone, Nefadar) is a psychoactive drug and antidepressant. [wikipedia]

関連反応

4 件

関連ノート

読み込み中…